December 2008
01: Prodrugs: How the Pros Do It?

November 2008
26: How Slow is Research Today? Here's a Recipe!
25: Avandia: Trouble, Run Head to Head
24: Two Drugs in One? Maybe Not.
21: The Back Door to the Stock Market
20: Noisy Numbers
19: Novartis and Reality
18: Cheese Dip and Hydrochloric Acid
17: Liable For Generics? You Are Now!
14: Sticking It to Proteins
13: The Yield Monster - And Its Friend, The Model Monster
12: Crestor: Would It Save Any Lives?
11: Wash Your Tubes; Mess Up Your Data
10: Crestor: Risks Up, Risks Down
07: System Biology: Ready, or Not?
06: CB-1 Obesity Drugs: Farewell to the Whole Lot
05: We Now Return to Our Regularly Scheduled Program
04: We Interrupt This Science. . .For Some Politics
03: Pfizer: Strategy, Layoffs, and Money

October 2008
31: Fructose In The Brain?
30: Lilly And Imclone: Not Expensive Enough!
29: Cutbacks - But Not As Bad This Time
28: Out the Door and Down the Stairs
27: Publish And Be Damned, Most Likely
24: BlackLight Power Responds
23: Merck Cuts Back (Again)
22: Blacklight Power: What on Earth?
21: Things I Won't Work With: Triazadienyl Fluoride
20: Fearful Symmetry?
17: Down The Chute in Phase III
16: Animal Models: How High to Set the Bar?
15: Where Are the Drugs?
14: Impact Factors: Can We Pretend That They Don't Exist?
13: Old School - Really Old
10: Kevin Trudeau: A Bit of Good News
09: More Glowing Cells: Chemistry Comes Through Again
08: A Green Fluorescent Nobel Prize
07: Nobel Season 2008
06: Imclone Really Does Get Bought
03: Day Off
02: Taranabant Is No More
02: Eli Lilly and Imclone: Sensible? Real?
01: Hard Times: A Manifesto

September 2008
30: Various Drug Industry News, None of It All That Good
29: Why Don't You Just. . .
26: Prasugrel Today?
26: Imclone's Secret Admirer
25: Pfizer: As We Speak?
25: Protein Folding: Complexity to Make More Complexity?
24: Ariad's Patent: A Court Rules
23: You Call That An X-Ray Source?
22: More Than This
19: Sunesis: No Substitutions Allowed?
17: Sugars: Still Crazy After All These Years
17: Ranbaxy: Cutting Corners, or Falsely Accused?
16: Neil Bartlett, 1932-2008
15: Extracting Money From Matthias Rath, For A Change
12: BMS vs. Imclone: Godzilla Exchanges Legal Language With Mothra
11: US and UK Biotech: Growth and Form
10: Pfizer / Bayer?
09: Antipsychotics: Do They Work For A Completely Different Reason?
08: The Complicated Causes of Cancer
05: Samurai! Unleash Your Drug Candidates!
04: X-Ray Structures: Handle With Care
03: Direct To Consumer Ads: Wasted Money?

August 2008
29: Sticky Containers, Vanishing Drugs
28: PNAS: Read It, or Not?
27: Crowded Proteins
26: New, Improved DNA?
25: How Not To Do It: Water Aspirators
22: Open Source Science?
21: RNAi: Bubble or Not?
20: Replacing What's Being Lost
19: Fighting Boredom, Profitably
18: Genentech and Roche, Act Two
15: Back
05: Roche Palo Alto: What's Going On?
05: Time Off
04: Job Seekers: Genentech, GSK, and Elsewhere
01: GSK Layoffs: Yes, Again

July 2008
31: Rember for Alzheimer's: Methylene Blue's Comeback
30: Bapineuzumab: Good For Anything or Not?
29: Iloperidone: A Schizophrenia Drug Goes Down For the Last Time
28: Questions You Don't Necessarily Want the Answers To . . .
25: Should Genentech Be a Part of Roche?
24: Confident
23: Patents Stopping an Alzheimer's Wonder Drug?
22: Vytorin: Another Round of Nasty Results
21: Backtracking, Necessary and Unnecessary
18: Lowe's Law of Diurnal Distribution
16: Receptors: Can't Live With 'Em, Can't Understand 'Em
15: Metabolic Hope Springs Eternal
14: Things I Won't Work With: Cyanogen Azide
11: Sharing the Enlightenment
10: More on Outsourcing
09: How's The New Boss Doing?
08: Glaxo Asks the Eurocrats
07: Pfizer's Prospects: Just Ducky
04: Happy Fourth of July
03: I Can Has Ugly Molecules?
02: More Pfizer Layoffs?
01: Leaving Comments: A Fix
01: The Gates Foundation: Dissatisfied With Results?

June 2008
30: Another Alzheimer's Compound Goes Down
27: Unknown - But You Can Buy It
26: Funding in the EU: The Simple Way
25: (No) Anarchy in the EU: A Report From Inside
24: Prasugrel: Come Back This Fall
23: Auroral Activity
19: Anarchy in the EU
18: All The Fat Cells You'll Ever Have - Sort Of
17: Protecting Amyloid's Parent?
16: Alli: "Underwhelming"
13: Elan Tries Again
12: Suits vs. Lab Coats?
11: More On the GSK Layoffs
10: GSK: Money-Green Outside, Pink-Slip Inside
09: An Impressive Nanolist of Nanocitations
06: Resveratrol in Mice
05: Merck, Vioxx: Seventeen and Three
04: Tote That Barge, Lift That Bale
03: Oops
02: A Breath of Fresh Air from Fuji

May 2008
30: Ah, Glassware
29: Nullius in Verba
28: Awash in Yen
27: An Eye For the Numbers
23: Up Close and Personal
22: Killing Proteins Wholesale
21: Lurching Around For Fun and Profit
20: The Miracle Solvent
19: Empty As Can Be
16: Nanotech Stem Cells, Order Now!
15: Copper: A Gentleman's Disagreement
14: Summer Student Time
13: In Which I Hate A Wonder Drug
12: Explaining It All
08: Merck Bails on Natural Products
07: Science By Country
06: Alzheimer's: A Report From the Front
05: Naming of Names
02: "Not Useful" Means "Not Approvable", Right?
01: O Pioneers!

April 2008
30: How Not To Do It: Diazomethane
29: Cordaptive Q and A
28: A Salute
25: Why Buy, Anyway?
24: $720 Million Worth of Sirtuin Research
20: Quick Note
18: Cut It Out. Cut It Out Now.
17: Getting Smarter Already?
16: Fun With Bacteria
15: Walk Around Some
14: Fifteen Minutes Shot
14: A Meditation on Solvents
11: Free Sushi in the Cafeteria!
10: Exubera, Safety, and No Guarantees
09: And You Thought Exubera Was A Disaster Before
09: Another Pop Quiz!
08: Fun With Tunichromes
07: Pre-emption For Real?
04: Another Cholesterol Medication Goes Down (Or Does It)?
03: Whose Guess Is Better?
02: Vytorin Numbers
01: Vytorin: It's A Pity

March 2008
31: Writing It Down
28: RNA Interference: Even Trickier Than You Thought
27: Start Small, Start Right
26: The Lucky Bonus Pack
25: Getting To Lyrica
24: That's Never Gonna Work
21: Pfizer Loses, So Far
20: Anonymity?
19: Now Your Liver Doesn't Have to Make It For You
18: A Solution, Courtesy of the MIT Faculty
17: You Get What You Pay For?
14: Pen and Paper
13: Pfizer vs. the NEJM: A Legal Showdown
12: Taranabant in Trouble?
10: Fill Out Your Pharma Brackets
10: Hits, Misses, and Some More Misses
07: Dissolve Your Troubles Away
06: Fakery And Its Ends
05: Smaller, Wetter, Harder to Work With
04: Off Target? Which Target Did You Mean?
03: Big Steaming Heaps of Fraud

February 2008
29: How Not To Do It: Column Chromatography
28: ApoE4: Test or Not?
27: Antidepressants: Depressing News or Not?
26: Sand Won't Save You This Time
25: More On Merck and Taranabant
21: New Tricks With Glassware
20: What You Become Known For
19: Day Off
15: Putting Out the Inevitable Fires
14: Getting Real With Real Cells
13: One Time Only. Or Maybe Just a Few.
12: DNA Forklifts, DNA Pliers
11: Fast Plaques in a Slow Disease
08: A Look Under the Hood
07: Write It Down, Write it Down
06: Dig the New Breed
05: Room At The Bottom, For Sure
04: How Many PPIs Does the World Need?
01: Commenting Issues
01: A Few Questions For My Fellow Pharma Chemists

January 2008
31: Drugs and Money
30: Recycle, Reuse, Republish
29: The Animal Testing Hierarchy
28: Laissez-Faire?
25: Extractions: A Way of Life
24: Cheap Happiness
23: Making the Adjustment to Smallness
22: These Fragments I Have Shored Against My Ruins
21: Breaking the Contract of Aging
18: Eat It, Breath It, Soak in It?
17: The EU Suspects No One, And Suspects Everyone
16: Judah Folkman
14: Vytorin, Holed Under the Waterline
11: They Can Be Ranked - Somehow
10: Drugs and Money and How It Feels
09: Ah, Politics
08: Rainbows and Fishing Expeditions
06: Dollar, Drugs, and Advertising
04: Plants For Cancer?
03: Top of the Heap
02: Back On the Air

December 2007
21: Winterize Your Ideas
20: Snow Day
19: Scrape Off Some Attitude
18: Hearing Footsteps
17: Le Dernier Cri
14: Biogen's Not For Buying. For Now.
13: Underperforming Triple Bonds
12: Med-Chem Layoffs, On the Front Page
11: A Bad Assay: Better Than None?
10: More Belts Tighten
07: Kids These Days!
05: Avandia: Going Under for the Third Time?
05: Unacceptable
03: The Big and the Little
03: Exciting Nonsense Wins Another One

November 2007
29: Neat! Wish It Were True!
28: Bad Luck For Novartis - And For Diabetics
27: Then I Felt Like Some Watcher of the Skies. . .
26: Still and All
25: You Do The Easy Stuff; I'll Do the Easier
21: Synthetic Prep of the Day: Chocolate Pecan Pie
21: Holiday Break
20: And It Goes Like This!
19: Depressing Figures for Acomplia
15: Quiz Time!
15: And Speaking of Discovering Things. . .
15: Maybe Not Improved, But Definitely New
14: How You Doin'? How's Everybody Doin'?
12: Here Be Chiral Dragons, With Fluorinated Fangs
11: A Real Genetic Headscratcher
09: One Year
08: Dumber in English?
07: Reasons to Be Different
06: Lights, Camera, Pharma!
06: Andy Grove: Rich, Famous, Smart and Wrong
05: Bright Lights and Applause?
04: Nerve, Lots and Lots of Nerve
02: One For the Brave

October 2007
31: Resistant Little Creatures
31: How Not to Do It: Hydrogen Bromide
29: What We Don't Know About Enzymes
29: Bacterial Infection: Better Or Worse Than Cancer?
25: Looking Backwards
24: Come On. Improve, Already.
23: Vial Thirty-Three, And More
22: Surveying the Exubera Crater
18: Understanding Dawns
17: Biogen on the Block?
16: Three Things You Need
15: Checking The Numbers on the Alzheimer's Test
15: Enzyme Humility
12: Unnatural, And Proud Of It
11: Let Us Now Turn To the Example of Yo' Mama
10: Ertl Wins: Down With Witchcraft
09: Nobel Chemistry Odds
09: Blogroll Update
08: Nobel Season
04: No Problem At All
03: More Layoffs, And What They Might Mean
02: Why Now, And Not Before?
01: All Sorts of Holes

September 2007
30: If Not This, What?
27: Thimerosal. Again.
26: Expensive Reading
25: Hey, Graduates! Negotiate Hard, You Hear, Now?
24: More Sirtuins With More Effects
24: Good News From the HR Department!
20: Go With The Er, Flow?
19: Fixing the Patent System?
19: The Good Old CombiChem Days
18: Ugly, But Useful
17: Arsenic, Patents, and the World
13: Don't Step Over It, Even If It's Right in Front of You
12: Drugs From Where?
11: Fresh Air, Or What Passes For It
10: Have We Got A Deal For You!
09: Guess That Market
06: Aromatherapy
06: More Things Than Are Dreamt Of
02: Renin, Wherefore Art Thou, Renin?

August 2007
31: Here It Goes
30: Elbow Room
28: Like Clockwork
27: Oh, Come On
26: Cheer Up
23: ". . . Jobs That Don't Exist"
21: Sorting Through the Piles
21: Ah, Rumors
20: The Current Cancer Long-Jump Record
17: More on Interview Seminars
14: Winning, By Tying Losers Together
13: Pilferage
12: These You Shall Have Always With You
09: Buying What You Can't Make? Or What?
08: Steve Ley, Azadirachtin, and Me (Very Much in That Order)
08: Exubera Spirals Toward the Drainpipe
07: Meet the Blogger?
06: Here, Fix This, Would You?
05: The Choir Hears It Again
03: Not Necessarily So
01: Run! Anthropologists!

July 2007
31: Incomprehension, Out For A Stroll
30: Avandia's Latest Round
27: You Discover It, We Sell It. Deal?
25: From the Sequencer to the Drugstore?
24: Godzilla vs. Mothra? Relman vs. Epstein!
23: Deactivation, After All
22: A Farewell to Tin
19: Hype In Spaaaace!
18: Over There, Behind That Stack of Whatchamacallits
17: Visfatin: Real Or Not?
16: European Drugs, American Drugs
15: Proteomics 101
13: Pour Encourager Les Autres
11: First Impressions
10: Travels In Numerica Deserta
09: Now With Ethyl Mesylate!
08: Starting Up Again

June 2007
26: Two Weeks Off
21: Real Life, Which Costs Real Money
20: Bigger, Tougher, Longer? Or Not?
18: Right Down the Alli
17: Access To Science
15: Rimonabant: Down to Earth
11: Rimonabant, Out In the Light
07: The Chamber of DNA Secrets
06: Massachusetts Moving
06: A Post I've Been Looking Forward to For Months
04: Phase Zero?
03: Pecunia Non Olet?

May 2007
31: The Avandia Wars Continue
29: Knowing What You Know. . .
25: More Avandia, And More on Marketing
24: Avandia: Trouble or Not?
23: Exalted Paper
22: Evolution In Action
20: Little, Big
18: But Enough About You
17: Beta-Secretase: Not So Fast?
16: Sunbeams, Single Electrons, and You
15: Into The Trackless Wilderness
14: Safer Every Day!
10: Alas, Dendreon
09: A New FDA?
09: Blogroll Update
07: Nonsense. On Stilts. Playing a Trumpet.
07: Brazil Raises The Pirate Flag
03: Forewarned is Forearmed
02: Obvious Ain't Obvious No More

April 2007
30: Outsourcing Blues?
29: Time To Conduct Some Business
26: Less Than Zero
25: A New HIV Therapy. Yawn?
24: Put Your Money Down
22: Melting Keys and Squishy Locks
20: Worst Animal Model: Nominations Are Open
19: Let A Thousand Flowers Bloom
19: The Big Time
18: Cro-MagnonDraw
17: The Doctorate and Its Discontents
15: Doctorate or Not?
13: Deep Breaths
12: Layoffs - Again
11: Exubera: This Time With Feeling
11: Amgen: The Pythian Oracle Laughs Again
10: Sulfur, Your Pal. Mostly.
08: Buy! Sell! Shout! Moan!
05: Awful, No Doubt. But Not As Awful as Before?
04: Linkage!
03: Vaccines Everywhere
02: Failure: Not Your Friend, But Definitely Your Companion
01: The HDL Compost Pile

March 2007
30: Rimonabant, Slowly
29: I Want A New Nitro
27: ACS Meetings
26: Vectibix Lurches A Bit
25: Wandering Through the Hydrides
23: Naked Synthesis
22: FDA Advisory Panels: Pay, No Play
20: AGI-1067: Dead or Alive?
19: Scientists, All Over
15: Lousy Reactions: Reader's Choice
14: Schering-Plough Goes Shopping
12: No Shortcuts
11: More Help Wanted?
08: How Not to Do It: More Diethyl Ether (Now With Extra Hardware)
07: Fish Nor Fowl?
07: Quietly Disappearing From the Skies
06: Decisions, Decisions
04: Calcium: A Backwater
01: How Not to Do It: Tertiary Butyllithium

February 2007
28: Have We Got a Job For You!
27: Wrong, But Still Convincing
26: Hedgehogs in Stockholm
25: Biotech's Net Loss?
23: F. A. Cotton, 1930-2007
22: Inspirational Reading?
22: Back From DC
21: CMPI Conference: Critical Path
21: CMPI Conference: CATIE and ALLHAT
21: CMPI Conference: Lunch With the FDA
21: CMPI Conference: Panel on the Politics of Drug Evaluation
21: CMPI Conference: Panel on Media Coverage
20: Something From Nothing
19: You Want Me to Just Talk? No Problem.
18: Wake Up and Smell the Solvents
16: Comments on Comments
14: Gene Patents, Part One: Genes As Chemicals
13: Crichton, Patents, and Genes
12: A Good Day's Work
12: Good Sense Breaks Out, Film at Eleven?
08: Depraved and Deprived
07: There's Toxicity and There's Toxicity
07: Vertex, Hepatitis, and Gripping the Arms of Your Chair
05: Good Mistakes?
05: A Break, Whether I Felt Like It Or Not
04: Going Hollywood, For Our Own Good?
01: How Not To Do It: Ruining Stuff

January 2007
30: BMY-SNY?
29: Open For Business
29: Blogroll Update
28: What Can Academia Do?
25: The Big Picture
25: Way Out Here
24: Back on the Air
17: Pfizer's Pfinances
16: How Not to Do It: Sophomore Organic Edition
15: Novo Nordisk Axes Med-Chem
14: Problems and Solutions
12: Ghost Town
11: An Innocent Question
10: Upside Down Activity
10: Reality, Here In This Little Dish
09: That Smell
08: PLoS One
07: Good Stuff and Bad Stuff
04: Take Your Shots (For Real, This Time?)
03: You'll Be Safe Under Here. Maybe.
02: That Can't Be Right - Try Again
02: And The Winner Is. . .
02: Out With the Old

December 2006
28: Cleans Down to What Should Be the Shine
26: Work At Home! It's Easy; It's Fun!
21: Holiday Schedule
20: Injustice
19: Hi, My Name Is [...]
18: ICOS In Pieces?
14: Love and Anger
13: Ars Longa, But Instructions to Authors Say "Brevis"
11: Torcetrapib: The Foil-Lined Hat Perspective
11: Old School? Same School!
08: Shameless Self-Promotion
07: Are You Experienced?
06: Bigger And Greasier
04: Too Near the Sun?
03: The Torcetrapib Catastrophe
01: Pfizer's Sizing

November 2006
30: The Other Side of the Table
29: Bad Interviews
27: The Litvinenko Case: More On Polonium and Alpha Particles
27: Polonium Poisoning
21: The Paper Mountain
20: Sell! (It's Not Just Me)
17: Ah, the Heck With the Error Bars
15: Vial Thirty-Three: Warp Drive
14: Where Do All The Chemicals Go?
14: Elsewhere
13: The Race Is On
10: Publish, Then Perish
09: Help Wanted - I Hope
08: Watch This Space
08: Links and Such
06: It Went Up Instead of Down
06: Chinese Med-Chem - In China, For Once
02: Hope, Springing Eternal And All That
01: And Thee, O Time
01: You Can't Make Money If You Don't Get Paid

October 2006
30: Blow The Trumpets
29: Family Portraits
26: It Should Work. It Just Doesn't.
25: Mass Spec on Mars
24: Naming of Names
23: Experimental Compound Codes
22: The Unattractive Truth
19: Levoglucosan
18: Peptides as Texts
17: Up Periscope And Fire All Bow Tubes
16: Show What You Know
15: German, Anyone?
12: More Handedness
11: On The Other Hand
10: Five Things I Haven't Used in Years
09: Forty NMR Magnets and 3000 Proteins Later. . .
09: Here and There
05: The Inscrutable French
04: Cheer Up, You Chemists
04: Another Chemistry Prize for Biology
03: Neuropeptide Y Dies, But It Never Surrenders
02: RNA Interference: Film at Eleven
02: Nobel Update: RNAi Wins
01: Test Your Skills!

September 2006
28: The Horse Latitudes
27: Nobel Fever Is Upon Us
26: Smell the Vibrations
25: A Spray-Painted Crystal Ball
24: Touch Me Not
22: Darn Photons
20: Imclone, Drama Queen of Biotech
19: By Any Other Name
18: Tenderbutton Calls It Quits
17: Tough Targets
14: Take Your Shots
13: Spectroscopic Days
12: Walking the Plank at Bristol-Myers Squibb
11: Enzymes Do Whatever They Want To
10: If You Want Your Explanations Overnight, It'll Cost You
07: Inherently Obvious - It's Obviously Inherent
07: Move On, Move On - Nothing To See Here. . .
06: Tell 'Em You Work On Something Else
05: Ariad's Patent Eviscerated
04: Plavix Plot Twists
01: Merck: Unfigure-outable

August 2006
30: Those Darn Invisible Creatures
29: Evil Thoughts of Evil Things
28: Paper on a Shelf
27: Floyd Landis: Could His Cortisone Treatments Exonerate Him?
24: Respect! Honor! Recognition! All For $149.95!
22: Explain This, Hot Shot!
15: Kevin Trudeau Was Born in 1963
15: Here and There
14: Tegenero, In Detail
13: Six Chem-Geek Questions
10: The Great Plavix Disaster
10: Airplanes and Chemicals
09: Ray Kurzweil's Future
08: Back in Court With Ariad and Lilly
07: A Vaccine Against Putting on Weight?
06: Where Do They Come From?
03: The Last Word on Eerie Glowing Labs
02: A Law of the Lab: Yields and Variations
01: Testosterone, Carbon Isotopes, and Floyd Landis

July 2006
31: Hobson's Choice
30: Pfizer's Man at the Top
27: Good News, Now That I Think About It!
26: Pfizer Recalculates
25: The Sun Shines at Pfizer
25: Back To Life
23: Hexacyclinol Rides Again
20: Peptide Craziness
19: Fuzeon's Fallout
18: Getting and Spending
17: Pounding Sand
16: The Future is Unwritten
13: A Friday Linkfest
13: J&J Shrinks Their Labs Again
11: More Purple Radiance
10: Aluminum: Friend or Foe?
09: Down the Chute: Your Call
07: Memo to the Public Relations Department
05: More Statin Skirmishing
04: Now With the Great Taste of Fish!
03: Pyrotechnic Days

June 2006
29: Rimonabant Arrives
28: Part Nine Hundred and Forty Two in a Series. . .
27: Academia in Summertime
26: Vioxx: 18 Months to Trouble?
25: Neurocrine's Choice
22: To The Third Darn Decimal Place
21: Waste O' Time Awards
20: Formally Undecideable
19: Rats Rule, Right?
18: More on Voodoo
15: And 0.04 Molar in Eye of Newt. . .
14: Vox Populi
13: The Fur Continues to Fly
13: Disapproval of Approvability
11: What's German For "Food Fight"?
11: Vial Thirty-Three: The Third Run
08: Peter Kim, So Far
07: Best When Used By. . .
06: Vial Thirty-Three Rides Again
06: Vial Thirty-Three: One Up, One Down
05: Hexacyclinol? Or Not?
04: Resistance Isn't Quite Futile
02: Brief Political Interlude
01: That Fount of Information We Call ASCO

May 2006
31: As Merck Caroms Off Another Tree
30: Things I Won't Work With: Frisky Perchlorates
29: Ask Not
25: Too Big to Discover Anything
25: Back on the Air
23: Can't Buy These Thrills
22: Merck and the Numbers
22: Mid-day Update
21: Chem-Geek Alternate History
20: Minute by Minute
18: A Question For the Crowd
18: Vial Number Thirty-Three
17: Merck's Latest Underwhelming Data
16: The New England Journal And Its PR Flacks
15: Leadership Secrets of the Data Fudgers
14: Cliff Diving
11: A Day at the Rota-Vap
10: A New Route to Tamiflu?
09: Ends, Means, Rats, and Dogs
08: A Natural Wonder Drug - Now What?
07: Yet Another Law
04: Ariad Wins a Round
03: Access to Phase I Drugs: A Constitutional Right?
03: Full Disclosure
03: Have The Rules Changed?
02: Things I'm Glad I Don't Do: Isolating Ciguatoxin
02: Travel

April 2006
30: All Natural
27: Golden Parachute, Still Packed and Ready
26: Jungle Rot
25: A Shot Across the Bow
24: Merck, So Far
23: You Can't Win If You Don't Play
20: Sulfurous Stenches: A Connisseur's Guide
19: Why All the Gloom?
18: There Is a Tide. . .
17: Reading Our Own Press Releases
16: Don't Know. Don't Care?
12: The Process of Process
11: Ariad's Day in Court
10: Linkorama
09: New Frontiers in Self-Deception
06: How Not to Do It: Distilling HMPA
05: Which World Do We Live In, Anyway?
04: Once More Into the Patent Breech
03: More On Doing Away With Patents
02: Down With Patents, Eh?

March 2006
30: Give The People What They Want
30: Missed One!
28: Rioting for Unemployment
27: Cleaning Out the Hood: An Internal Monologue
26: A Word to the Wise About TGN1412
24: Explosion News
24: Can You Say "Uebernahmeangebot"?
23: Crystals of Doubt
22: A Lengthy Day
21: Nitromed's Slow Decline
20: Grad School, Blogged
20: TNG1412: Was There a Warning?
17: Update on TGN1412
16: Price Gouging or Not?
15: No Immunity From Immunity
14: Neowater Replies
13: The Big Statin Pillow Fight
12: Bubble Fusion Implodes
09: Wonder Drug, Indeed
09: Men and Women and Science and Jobs
08: How Not to Do It: Liquid Nitrogen Tanks
08: Things Turn Nasty
06: Man Hands on Misery to Man
05: Journal of Biological Chemical Biochemical Chemical Biology
02: Technical Difficulties
02: Procter and Gamble Throws in the Towel
01: Deception Begins at Home

February 2006
28: More on Outsourcing
27: But At My Back I Always Hear. . .
26: Tied to the Mast
24: What's French for "Trust Us"?
23: Blogroll Revamp
22: NEJM vs. Its Contributors, Round Two
21: Gold and Lasers
20: Rimonabant Bangs Into. . .Something
19: Because I Never Lie, and I'm Always Right
16: What's It Worth to You?
15: Pfizer Takes a Deep Breath
14: First Slide, Please
13: Heart-Warming Stories of Success
12: Kinase Inhibitors: Doomed From the Start?
09: Ban Intelligent Design?
08: Garnier Strikes Back
07: Return of Neowater
06: J&J Shakes Things Up
05: Stream of Consciousness
02: Nanotech Wonder Water?
01: The Good New Days

January 2006
31: Here's A Shovel. Could You Dig Yourself In Some More?
30: Forecast: Rain, Eventually
29: Name Reactions for One Thousand, Alex
26: Ah, It's Fine. Just Send the Darn Thing Out Already.
25: If It's Not One Thing. . .
24: The Examiner Finally Snaps
23: Merck versus the New England Journal
22: Full Disclosure
19: But His Name Lives On. . .
19: Tamiflu: Good For Anything, Or Not?
18: A Scientific Aptitude Test?
17: Gimme That Old Time Reaction
17: Dangerous Thoughts
16: Various Updates
15: The FDA Loosens Its Tie
13: How Not to Do It: Ether Peroxides
12: Plenty of Tar to Go Around
09: Stem Cell Disaster
08: My Shopping List
05: Ugly, But Effective
04: Mice, Humans, and Cancer
03: Pemoline Problems
03: Comments Welcome - Really
02: A Scientist's Resolutions

December 2005
29: Outside Reading
27: What Makes an Ugly Molecule?
23: Sort Of Like A Wine Cellar
22: Poor Put-Upon Intelligent Design
21: Another Shot at Cancer
20: The Dover Decision Comes Down
20: Does Celebrex Have A Future At All?
17: How Not to Do It: Bromine
15: Attack of the Angry Viruses
14: An Expensive Way Back for Celebrex
13: The New England Journal of Legal Immunity?
13: Grand Rounds
12: Play by Play in the Lab
09: A Vioxx Bomb Drops. Or Does It?
07: The Hard News on Cancer
06: Well-Rounded?
06: Grand Rounds Today, and Next Week
05: Home Sweet Home
04: Not On the Same Page
02: The Bell Finally Tolls for Peter Rost
01: Rigel's Puzzling Failure

November 2005
30: Okadaic Acid Makes Vanity Fair
30: Merck Update
29: Ghrelin and Obestatin
28: Merck, Finally
27: Hire the Thoroughbreds?
25: Instead of Working
22: Serono's Suitors
21: Run, Do Not Walk, To The Nearest Exit
21: Old Standbys
20: Sir2 Surprise
17: A Man, A Book, and a Plan. Several Plans.
16: What Sort of Training?
15: Statin Showdown
14: One Darn Miracle After Another
13: Arcadia's Furnishings
11: Gene to Drug: You Bet
10: . . .And That Settles It
09: Cash For Vaccines
08: University of Drug Discovery?
07: Intelligent Design, Molecule By Molecule
06: The Dover Decision
03: Merck Off the Mat
02: The Flu Plan, Part Two: Antiviral Drugs
02: The Flu Plan, Part One: Vaccines
01: Molecular Modeling Cage Match

October 2005
31: Five Questions
30: Gooooaaaal!
28: Pargluva Goes Down?
27: Imclone Revisited
26: The Latest in Pharmaceutical Technology
25: Start Your Engines
24: Hype or Hope?
23: The Tar Pit Beckons
20: This Had Better Be Good
19: Complaints From a Fossil
19: Procrastination Assistance
18: Waiting for Pargluva
17: James Cramer, Biocryst, and You
16: Matthias Rath, Pioneer
13: Buy! It's More Expensive Than Usual!
12: The Undefeated Brazilian Team
11: The Old Stuff
10: Time and Chance
09: Needs and Wants
06: The Great Divide
06: Outside Reading, and Plenty of It
05: Human Genome Science Hits the Wall
05: Metathesis Nobel!
03: Where Do the Good Ones Go?
03: Well Deserved
02: A Piece of the Action

September 2005
30: And Another Thing. . .
29: The Hazards of Molecular Modeling
28: Clamping Down, or Loosening Up?
27: Tribes
26: Antivirals "Gathering Dust"?
25: Report From What I Think is the Frontier
22: By a Nose in a Head to Head
21: No Clear Winners
20: Say It Again!
19: Klotho: Sooner Than You Think?
18: A Sensitive Guy
15: Pretty Much the Reason You'd Think
15: Here and There
13: It Pours on Ligand
12: ". . .And to Furbish Falsehoods For a Magazine"
11: Remind Me Not to Do This Again
08: Muraglitazar's Turn
07: The Tiniest Doors Begin to Open
06: